Oxaliplatin has emerged as a major chemotherapeutic drug in the treatment of advanced colorectal cancer, yet like most conventional cancer therapeutics, its efficacy is often compromised due to p53 mutations. Unlike oxaliplatin, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in a p53-independent manner, and chemotherapy is known to overcome tumour resistance to TRAIL-induced cell death in most cancer cells. Using a panel of colon cancer cell lines, we assessed the ability of oxaliplatin to sensitize to TRAIL-induced apoptosis. We demonstrate that while both drugs additively or synergistically induced apoptosis in almost all cell lines tested, p53 wild-type colon cancer cells such as HCT116, LS513 or LS174T remained resistant. Impaired TRAIL-induced cell death resulted from a strong p53 dependent, oxaliplatin-mediated, DcR1 receptor expression increase. According to our finding, downregulation of DcR1 using siRNA, in p53 wild-type colon cancer cells, restored oxaliplatin/TRAIL synergistic apoptotic activity. On the contrary, exogenous DcR1 overexpression in SW480, a p53-mutated cell line, abolished the synergy between the two drugs. Altogether we demonstrate for the first time that p53 negatively regulates oxaliplatinmediated TRAIL-induced apoptotic activity through DcR1 upregulation. Our findings could have important implications for future therapeutic strategies, and suggest that the association oxaliplatin/TRAIL should be restricted to patients harbouring a non-functional p53 protein.
Introduction
Colorectal cancer is one of the leading causes of cancerrelated death worldwide (van Geelen et al., 2006) . After surgery, up to 50% of patients will relapse and die from metastatic disease (Gramont, 2005) . The development of colorectal carcinomas is caused by multiple genetic changes, including frequent inactivating mutations of the p53 gene (Grady and Markowitz, 2002) . The wildtype p53 gene plays a key role by inducing cell cycle arrest and activating the intrinsic apoptosis pathway in response to a large variety of chemotherapeutic agents (van Geelen et al., 2006) .
Although oxaliplatin-based drug combinations have improved response rates in the treatment of advanced colorectal cancer, chemoresistance remains a major problem. It is therefore important to identify prognostic factors that can help to develop new patient-tailored treatment strategies. We previously showed that oxaliplatin, used in a clinically relevant manner, mainly acted in a cytostatic fashion (Toscano et al., 2007) , although in some studies, using long-term treatment schedules, this agent was shown to induce apoptosis through the mitochondrial intrinsic pathway (Shankar and Srivastava, 2004) .
Unlike oxaliplatin however, tumour necrosis factorrelated apoptosis-inducing ligand (TRAIL) activates the extrinsic apoptosis pathway in most tumour cell types, but is unable to trigger cell death in normal cells (Ashkenazi, 2002) . TRAIL binding to its cognate agonistic receptors, DR4 and DR5, induces the formation of the death-inducing signaling complex, a multimolecular platform that allows the activation of the initiator procaspases-8 and -10, which triggers the proteolytic caspase cascade leading to apoptosis (Thorburn, 2004) . Cross talks exist between the extrinsic and the intrinsic pathway. In some tumour cells, the mitochondrial amplification loop is required to engage the apoptotic machinery upon TRAIL stimulation (Scaffidi et al., 1999) . On the other hand, some chemotherapeutic drugs involve, at least partially, the engagement of death domain-containing receptors to trigger cell death (Micheau et al., 1999) . Recent evidence indicates that both tumour and normal cells can acquire resistance to TRAIL-induced killing by upregulating either of the two antagonistic receptors, DcR1 and DcR2, which do not transfer any apoptotic signal (Davidovich et al., 2004; Clancy et al., 2005; Merino et al., 2006) , indicating that the four TRAIL receptors are involved for regulating TRAIL-induced apoptosis (Kelley and Ashkenazi, 2004; Bouralexis et al., 2005; Merino et al., 2007) .
Combination of compounds that induce genotoxic stress to ligands of the TNF family, that activate death receptors, was demonstrated to generate synergistic antitumour responses in several human tumour types and to overcome tumour resistance (Ashkenazi, 2002; Wajant et al., 2005) . Modification of TRAIL agonistic receptor expression by chemotherapeutic agents was shown to account for TRAIL-induced sensitization in some cells (Nagane et al., 2000; Bouralexis et al., 2003) . Although all four receptors have been described as p53 target genes, the importance of p53 in chemotherapy-mediated sensitization to TRAIL remains unclear (Jang et al., 2004) . The goal of our study was thus to clarify the role of p53 in controlling TRAIL receptor expression in colon cancer cells treated with oxaliplatin, and to determine its impact on oxaliplatin-induced sensitization to TRAIL.
Results
Oxaliplatin and TRAIL combination exhibits synergistic toxic effects on resistant colon cancer cell lines Sensitivities to oxaliplatin-or TRAIL-induced cell death in the six colon cancer cell lines tested, as measured using (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-tetrazolium bromide) assays (MTTs), varied from one cell line to another (Table 1) . However, as shown in Figure 1a , oxaliplatin and TRAIL exerted important synergistic effects in SW480, HT29 and V9P cells (combination index (CI), 0.76±0.06, 0.56±0.11 and 0.45±0.15, respectively), but nearly additive effects in LS1034 and Isreco1 cells (CI, 0.91 ± 0.10 and 1.02 ± 0.04, respectively), and antagonistic effects in the HCT116 cell line (CI, 1.28 ± 0.02). Synergy was also evidenced using cytotoxicity assays as illustrated in HT29 cells (Figure 1b) . Interestingly, the more the cell lines were resistant to TRAIL, the more oxaliplatin and TRAIL showed synergistic toxicity ( Figure 1c , left graph). In contrast, there was no correlation between CIs and sensitivities to oxaliplatin (Figure 1c, right graph) .
Used alone at 5 mM, a sub-toxic concentration, oxaliplatin failed to induce detectable poly-ADP ribose polymerase (PARP) cleavage in the six colon cancer cell lines tested. In contrast, TRAIL used at 10 ng ml À1 resulted in PARP cleavage in all but two (HT29 and V9P, which are resistant to TRAIL) cell lines (Figure 2a) . Combining oxaliplatin to TRAIL however sensitized LS1034, SW480 and V9P cells to cell death through a mechanism that involved the apoptotic machinery as evidenced by PARP cleavage (Figure 2a ), but failed to sensitize HT29 cells at that concentration. Considering two cell lines, from our cell panel, exhibiting different response to the TRAIL/ oxaliplatin combination, the HCT116 and the HT29, at concentrations that inhibit growth by 50% (IC 50 ), we could demonstrate that in contrast to TRAIL, oxaliplatin never triggered caspase-3 activation (Figure 2b ). However, when cells were treated with both drugs, caspase-3 activation increased as compared to TRAIL treatment in HT29 cell line but remained undetectable in HCT116 cells. In line with this finding, a synergy between oxaliplatin and TRAIL was observed on PARP cleavage only in HT29 cells (Figure 2c) . Moreover, the percentage of sub-G 1 cells was significantly higher in HT29 cells treated with the oxaliplatin/TRAIL combination as compared to any single drug (Figure 2d ), while the opposite effect was observed when HCT116 cells were treated with both drugs, as compared to TRAIL. According to our previous findings, oxaliplatin-treated p53 wild-type HCT116 cells exhibited no DNA accumulation in the sub-G 0 /G 1 phase, no caspase-3 activation nor PARP cleavage but a G 0 /G 1 arrest that impaired cell growth (Toscano et al., 2007) . These results indicate that the synergistic apoptotic activity induced by associating oxaliplatin and TRAIL could be controlled by p53, since only p53-mutated cell lines responded in a synergistic manner to that combination, whereas the p53 wild-type cell line HCT116 exhibited antagonism to the combined treatment.
Antagonism between oxaliplatin and TRAIL in the HCT116 cell line is tightly dependent on p53 status We therefore hypothesized that the p53 status could play an important role in controlling the synergistic apoptotic activity in colon cancer cells. To address this question, we took advantage of the HCT116 p53 À/À cell line as compared to the parental p53 wild-type HCT116 and the p53 mutant HT29 cell lines, to determine both p53 protein expression upon drug treatment and synergistic apoptotic activity. Using these cellular systems, we could show that p53 was only upregulated in the parental HCT116 cell line, upon oxaliplatin or oxaliplatin/TRAIL combined treatments (Figure 3a) . Its expression was minimally affected in the p53 mutant HT29 cell line which expresses high expression level of a mutated form of p53 at the steadystate level, and the HCT116 p53 À/À cell line remained negative for p53 whatsoever the treatment. This p53 À/À cell line exhibited increased resistance to both oxaliplatin and TRAIL, ranging from 7-and 10-fold increase as compared (Figure 3b) , with a CI close to that of the p53 mutated-type HT29 cell line. Moreover, the percentage of apoptotic HCT116 p53 À/À cells was significantly higher when the two molecules were administrated in combination as compared to TRAIL administration alone (Figure 3c ). These results suggest that wild-type p53 protein impairs the synergy between oxaliplatin and TRAIL in the HCT116 colon cancer cell line.
Oxaliplatin induces DcR1 overexpression in HCT116 cells
Considering that all four TRAIL receptors are known transcriptional targets of p53 (Sheikh and Fornace, 2000) , we analysed their expression levels before and after oxaliplatin treatment in our colon cancer cell line panel. Using flow cytometric analysis, we could demonstrate a significant inverse correlation (from HCT116 to V9P cells, fold decrease 3.4; R 2 ¼ 0.781) between resistance to TRAIL and the expression level of DR4. Upon oxaliplatin treatment, no significant modification of TRAIL receptor expression in all five p53-mutated cell lines was observed (Figure 4a (Figure 5c ), indicating that restoration of the apoptotic synergy in cells treated with the combination oxaliplatin/TRAIL is not due to the mere increase in IC 50 TRAIL , but to the inhibition of DcR1 expression at the cell surface. To determine whether our finding can apply to a broader panel of cell lines, we performed similar experiments using two other human colorectal cancer cell lines, the LS513 and the LS174T, both harbouring wild-type p53. In both cell lines, and similarly to HCT116 cells, oxaliplatin strongly induced an increase in DcR1 expression as measured by flow cytometry (Figure 6a ). Inhibiting DcR1 upregulation using specific siRNAs in oxaliplatin-treated LS513 (Figure 6b , left) or LS174T (Figure 6b, right) , cells restored oxaliplatin-induced sensitization to TRAIL-induced cell death as evidenced by the decreased CI values and shifted isobolograms below the additivity curve (Figure 6c ). In LS513 and LS174T cells transfected with a NS siRNA, p53-mediated DcR1-dependent antagonistic activity was unaffected with CI values remaining high (1.23 ± 0.07 and 1.14 ± 0.03, respectively). Moreover, similar to the HCT116 cell line, IC 50 TRAIL of LS513 and LS174T cells Oxaliplatin/TRAIL combination in colon cancer F Toscano et al transfected with DcR1 targeting siRNAs did not significantly differ from that of cells transfected with a NS siRNA duplex, indicating again that the restored synergy was not due to an abnormal increase in IC 50 TRAIL (Figure 6d ). Taken together, our results demonstrate that the p53-dependent oxaliplatin-induced DcR1 increased expression is responsible for the antagonism between oxaliplatin and TRAIL in a panel of p53 wild-type cell lines.
Exogenous DcR1 overexpression suppresses synergy between oxaliplatin and TRAIL in p53 mutated-type cell lines To further evaluate the role played by DcR1 in controlling cellular response to apoptosis induced by the combined treatment associating oxaliplatin and TRAIL, DcR1 was stably overexpressed in the p53 mutated-type cell line SW480 by use of a retroviral expression system approach. Cell surface expression of DcR1 was checked by flow cytometry. Compared to SW480-CTR (transduced with an empty pMSCV-based vector) or to parental SW480 cells, SW480-DcR1 (transduced by a pMSCV-based vector encoding DcR1) expressed high levels of DcR1 at the cell surface (Figure 7a ). Importantly, in these settings, while oxaliplatin sensitized parental or SW480-CTR cells to TRAIL-induced cell death (Figures 1a and 7b) to a similar extent (CI, 0.76 ± 0.06 and 0.66 ± 0.09, respectively), cells harbouring DcR1 at the cell surface remained resistant to TRAIL-induced apoptosis (Figure 7b ), exhibiting nevertheless a lower CI than those of p53 wild-type colon cancer cells.
Altogether our results provide strong evidence that oxaliplatin-induced, p53-mediated, upregulation of DcR1 can hamper sensitization to TRAIL-induced cell death in colorectal cancer cell lines.
Discussion
Resistance to chemotherapy is a major issue in the management of metastatic colorectal cancer. Understanding the molecular pathways responsible for either synergy or antagonism of different drug combinations is a major step in the development of new therapeutic agents. Pre-clinical studies have shown that TRAIL treatment overcomes chemoresistance from a large variety of anticancer drugs in different cancer types (Yagita et al., 2004; Merino et al., 2007) . Accordingly, we show here that combining oxaliplatin with TRAIL leads to an important overall beneficial tumouricidal effect in most colon cancer cell lines tested, particularly when cells exhibit high resistance to TRAIL. However, we identify for the first time a specific antagonistic mechanism occurring through DcR1 in p53 wild-type cells, the significance of which is discussed below.
Sensitization to TRAIL-induced apoptosis by chemotherapy both in vitro and in vivo (xenograft) in a large panel of cancer models is now well established (Yamanaka et al., 2000; Vignati et al., 2002; Jin et al., 2004) . One study reported TRAIL-enhanced apoptosis in response to chemotherapy in a large panel of colon cancer cell lines, including in the p53 þ / þ or p53
HCT116 cells (Galligan et al., 2005) . In contrast, our results are in favour of an antagonism between the two molecules in p53 wild-type cells such as HCT116, LS513 and LS174T. We believe that such a discrepancy could be explained by the differences in experimental settings used in both studies. First, to mimic the duration of oxaliplatin infusion in human therapy, we used in our work a different treatment schedule and exposed tumour cells to shorter period of time with oxaliplatin (2-h exposure), while most studies generally expose tumour cells to longer periods ranging from 24 to 72 h. Second, systematic determinations of CIs and isobolograms were performed only in our study, according to the IC 50 of both oxaliplatin and TRAIL of each tested cell line. Oxaliplatin/TRAIL combination in colon cancer F Toscano et al Therefore, since in our settings both drug concentrations and exposure times approach clinical parameters, we believe that our results should prove probably more useful to clinicians than most studies involving longer time schedules. Furthermore, although it has been reported that treatment with oxaliplatin sensitized both p53 wild type and HCT116 p53 À/À cells to TRAILinduced apoptosis (Galligan et al., 2005) , our results demonstrate that this might not be actually the case in patients receiving lower drug amounts in a limited period of time, especially with patients harbouring p53 wild-type colorectal tumours. Nevertheless, combining oxaliplatin to TRAIL treatments in the remaining 60% patients suffering from colon cancers which exhibit p53 mutation could be beneficial.
It is thought that p53 induces apoptosis by transcriptionally modulating the expression of pro-apoptotic target genes (Oren, 2003) , including DR4 and DR5 (Liu et al., 2005) . Despite previous findings demonstrating that various anticancer drugs induce an increase in either DR4 or DR5 membrane expression (He et al., 2004; Kim et al., 2004) , we found that oxaliplatin treatment had no major effect on DR4 and DR5 cell surface expression in all tested cell lines, independently of the p53 status. In addition, DcR1 and DcR2 genes, encoding two antagonistic TRAIL receptors which exhibit differential TRAIL inhibitory properties (Merino et al., 2006) , were also shown to be regulated at the transcriptional level by p53 (Ruiz de Almodovar et al., 2004) . Interestingly, in our hands, while membrane expression levels of DcR1 and DcR2 remained unchanged in HCT116 p53 À/À cells or in p53 mutatedtype cell lines after oxaliplatin treatment, DcR1 expression level increased significantly in all p53 wild-type cell 
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F Toscano et al lines tested. On the contrary, DcR2 expression was not detected in these cells and its expression was not regulated by p53. While all TRAIL receptor genes are putative p53 targets, it is not clear for the moment why only DcR1 is upregulated and why in some other conditions only DR4 or DR5 are regulated by p53. Our finding could be nevertheless important to antitumoural approaches aiming at combining oxaliplatin and TRAIL to cure patients since we provide for the first time an indication that DcR1 may hamper oxaliplatin-induced sensitization in patients harbouring wild-type p53. DcR1 is an antagonistic receptor that is able to titrate TRAIL ligand and thus to inhibit TRAILinduced cell death (Pan et al., 1997; Merino et al., 2006) , or lead to tumour resistance (LeBlanc and Ashkenazi, 2003) . Its regulation by the p53-suppressor gene could explain the appearance of some TRAIL-resistant tumours in relapsing patients treated with chemotherapeutic drugs. In vitro, in cells expressing wild-type p53, preventing oxaliplatin-induced DcR1 overexpression using RNA interference restored the synergistic sensitizing activity of oxaliplatin towards TRAIL-induced cell death. On the contrary, exogenous DcR1 overexpression, in p53-mutated cells, prevented oxaliplatininduced sensitization to TRAIL-apoptosis. Thus, further studies are required to determine whether tumour cell p53 status may help in selection of patients recruited to therapeutic protocols involving oxaliplatin and TRAIL. These findings might be particularly relevant to ongoing clinical trials aiming at evaluating the anti-tumoural properties of TRAIL combined with chemotherapy. Alternatively, patients exhibiting wild-type p53 tumours could benefit from ongoing phases I-II clinical trials using either agonistic anti-DR4 or anti-DR5 Oxaliplatin/TRAIL combination in colon cancer F Toscano et al antibodies in human colon cancers (Motoki et al., 2005; Pukac et al., 2005; Mita et al., 2006) . We have demonstrated recently that an agonistic antibody targeting DR5 in vitro could trigger apoptosis in cells expressing the corresponding agonistic receptor even when cells harbour either of the antagonistic receptors, DcR1 or DcR2, at their cell surface (Merino et al., 2006) . Based on these demonstrations, one could speculate that oxaliplatin would sensitize colorectal cancer tumours to either DR4-or DR5-induced cell death irrespective of p53 status. This combination is now to be tested in animal models.
Altogether our data drive an important hope regarding the potential in vivo synergy between oxaliplatinbased chemotherapy and TRAIL or TRAIL-related agonistic antibodies, namely the possibility to target specifically p53 mutated or p53 wild-type colorectal tumour cells with combined therapeutic approaches associating either TRAIL or agonistic anti-DR4 and anti-DR5 antibodies, respectively. Oxaliplatin/TRAIL combination in colon cancer F Toscano et al
Materials and methods
Cell culture and drug treatment Human colorectal cancer cell lines HCT116, Isreco1, LS1034, SW480, V9P, HT29, LS513 and LS174T (gift of Dr R Hamelin, INSERM U762, Paris, France) and the HCT116 isogenic derivative with a targeted inactivation of p53 (HCT116 p53
, gift of Dr C Dumontet, INSERM U590, Lyon, France) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Cergy Pontoise, France) supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine and antibiotics (streptomycin 10 mg ml À1 and penicillin 10 000 IU ml À1 ) in a humidified 5% CO 2 incubator at 37 1C. Fresh solutions of oxaliplatin (Eloxatin, Sanofi Aventis, Paris, France; 5 mg ml À1 ) were mixed in complete medium, added to adherent cells for 2 h, then removed and replaced with fresh medium alone or with medium containing recombinant human TRAIL (Peprotech, Levallois Perret, France; stock solution 50 mg ml
À1
).
Drug sensitivity assay Determination of drug cytotoxicity was performed using MTT (Sigma, St-Quentin Fallavier, France) as previously described (Toscano et al., 2007) . Cells (10 000 per 100 ml) were seeded into 96-well plates, and allowed 24 h for attachment. Medium was then replaced with fresh medium containing serial concentrations of oxaliplatin (0-450 mM) for 2 h. Cells were then washed, and treated with a range of concentrations of TRAIL (0-500 ng ml
) for 70 h. Sensitivity to drugs was expressed in terms of the concentration of drug required to inhibit 50% of cell growth (IC 50 ).
To determine the effects of oxaliplatin and TRAIL on cell proliferation, cells were seeded on six-well plates (100 000 per well), treated 24 h later with oxaliplatin for 2 h and then medium was replaced by complete medium with or without TRAIL. Colonies were visualized 72 h after treatment by crystal violet staining.
Determination of drug interactions
The CI (Chou and Talalay, 1984) For isobolograms (Steel and Peckham, 1979) , data were graphed by plotting IC 50 oxaliplatin on the x axis, IC 50 TRAIL on the y axis and connecting the paired points with a diagonal line (additivity). Synergism is encountered if the experimental points (IC 50 oxaliplatin/TRAIL and IC 50 TRAIL/oxaliplatin ) fall below that line, whereas antagonism occurs if the points lie above it.
Immunoblotting Cells were collected 8 h after the beginning of treatment and immunoblot analyses were performed as previously described (Toscano et al., 2007) , with the following appropriate monoclonal antibodies: anti-p53 (clone DO7, Dako, Trappes, France); anti-PARP (clone C2-10, BD Biosciences, Le Pont-deClaix, France) and anti-tubulin-a (Sigma). After incubation with the secondary antibody conjugated to horseradish peroxydase, blots were revealed using the electrogenerated chemiluminescence method (Covalab, Lyon, France).
Caspase-3 activity Cells were scraped and homogenized in 50 ml of lysis buffer. Extracted proteins were diluted in dilution buffer to obtain 150 mg final concentration, and analysed using the Caspase-3 Colorimetric Assay (R&D Systems, Lille, France) according to the manufacturer's instructions.
Flow cytometry
For determination of sub-G 1 population, cells were seeded at 4 Â 10 5 cells per well in six-well plates. After 24 h, cells were treated with their respective IC 50 oxaliplatin for 2 h, then with fresh medium or with their respective IC 50 TRAIL . Twenty-four hours post-treatment, cells were harvested in phosphatebuffered saline (PBS) and pelleted by centrifugation (400 Â g, 4 1C, 5 min), then washed twice with a sodium citrate/sucrose/ dimethyl sulfoxide buffer and stained with propidium iodide according to the manufacturer's instructions (Cycle Test Plus DNA reagent staining kit, BD Pharmingen, Le Pont-de-Claix, France). For each sample, data were analysed as previously described (Toscano et al., 2007) .
For analysis of cell surface receptor expression, cells were treated with their respective IC 50 oxaliplatin for 2 h. Oxaliplatin was then replaced by complete DMEM and cells were incubated for 22 h. Cells were washed in PBS, harvested in PBS-10% FBS and stained with DR4, DR5, DcR1 or DcR2 antibodies (R&D Systems) for 45 min at 4 1C. Cells were then washed three times with PBS, incubated for 45 min at 4 1C with secondary anti-mouse antibody conjugated with FITC (Beckman Coulter, Roissy, France) in PBS-10% FBS and washed twice with PBS before analysis.
All analyses were performed on a Dako flow cytometer (Carpinteria, CA, USA), using the FloMax program.
DcR1 expression by enzyme-linked immunosorbent assay DcR1 protein content in the cell lysates obtained 24 h after drug treatment was quantified by ELISA according to the manufacturer's instructions (Diaclone, Besanc¸on, France). (antisense). HCT116, LS513 and LS174T cells were transfected with siRNA using Lipofectamine 2000 (Invitrogen). The final DcR1 or NS siRNA concentrations were 50 nM. Five hours after transfection, medium was replaced by complete DMEM. Cells were transferred 2 h after into 96-well plates then treated with oxaliplatin and TRAIL, as previously described, 24 h after transfection.
Retrovirus production and cell transduction
The retroviral vector pMSCV-puro and the generation of viruses have previously been described (Micheau et al., 2001) . DcR1 full-length construct was subcloned from pCR-3 vector (Invitrogen) to pMSCV-puro. SW480 cells were transduced for 16 h with viral supernatants containing polybrene (8 mg ml
À1
), washed in PBS and cultured in complete medium containing puromycin (2.5 mg ml
Statistical analysis
The data are the mean values ± s.e.m. of at least three separate experiments. Statistical significance of results (Po0.05) was analysed using a Student's t-test.
